Rainbow’s viva happened already back in August, but now the Award has been confirmed after completion of all formalities. Rainbow’s project, co-supervised by Dr Gilbert Fruhwirth and Prof Ramón Vilar, focused on building a probe that allowed tumour imaging at a whole-body and microscopic level, while selectively delivering a highly cytotoxic agent into tumours.
Proud to see our latest work published by the British Journal of Cancer: https://lnkd.in/djxJhGQ.
We proposed a migrastatic drug development pipeline. As part of the pipeline, we provide a new traceable spontaneous melanoma metastasis model for in vivo quantification of metastasis and anti-metastatic effects by non-invasive imaging.
This was a fantastic team effort between Vicky Sanz Moreno‘s team at Barts Cancer Institute and ourselves at King’s College London – Massive THANKS to everybody involved!
#cancerresearch #metastasis #drugdiscovery #imaging #celltracking #skincancer
Sharing here a recent review we contributed to as part of an international consortium including the results of a multi-stakeholder survey by the HESI CT-TRACS Committee aimed at identifying areas of interest to help ensure the safe use of cellular therapeutics in the clinic.
We offer a brief overview of available technologies and then highlight the areas of interest from the survey by describing how imaging technologies can meet those needs. Areas of interest include imaging of cells over time, sensitivity of imaging modalities, ability to quantify cells, imaging cellular survival and differentiation, and safety concerns around adding imaging agents to cellular therapy protocols.
#advancedtherapies #cellandgenetherapy #celltherapy #immunotherapy #celltracking #HESI #healthcare #emergingmarkets
… for passing her PhD viva with hardly any corrections. What a great achievement on the interface of imaging chemistry and imaging biology, and all in less than 3.5 years.
as we are very happy to see Yasmin pass her viva without any corrections !!!
Through a great team effort we demonstrated quantitative non-invasive Treg tracking over weeks.
This addressed a fundamental need in Treg therapy development and offered a clinically compatible methodology for future Treg therapy imaging in humans.
Applying this approach, we also showed that Treg trafficking to skin grafts was regulated by the presence of recipient Gr-1+ innate immune cells.
Now available in Molecular Therapy – Methods Clinical Development.
..we were scattered (with Rico and Qi on the other side of the planet)
BUT we still had great FUN!!!
We are so proud of Ines for these two excellent talks about her PhD work and about the important role of technologists in Nuclear Medicine.
in vivo PET tracking using human NIS as a reporter gene and employing already available radiotracers
(i) enables accurate quantification of CAR-T tumour retention and
(ii) is not damaging the therapeutic cells.
Now available in Molecular Therapy: https://lnkd.in/dTQT2Me
Great work by Candice, Madeleine and Adeel reviewing and explaining how non-invasive reporter gene imaging can aid the development and clinical translation of cell-based therapies. We describe the underlying principles governing non-invasive in vivo long-term cell tracking in the preclinical and clinical settings, including available imaging technologies, reporter genes, and imaging agents as well as pitfalls related to experimental design.(https://doi.org/10.1016/j.ymthe.2020.03.016)